CDK4 and cancer: If, in addition to Rb, Cdk4/6 also directly control RNAPII activity during cell cycle entry via CTD phosphorylation, then the molecular mechanism by which Cdk4/6 inhibitors exert their effect in the treatment of cancer may need to be revisited.